Lazarus, ?; Anstee, Quentin M.; Hagstrom, Hannes et al.
Defining comprehensive models of care for NAFLDNATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY. Bd. 18. H. 10. 2021 S. 717-729
Rosigkeit, Sebastian; Kruchem, Marie; Thies, Dorothe et al.
Definitive evidence for Club cells as progenitors for mutant Kras/Trp53-deficient lung cancerINTERNATIONAL JOURNAL OF CANCER. Bd. 149. H. 9. 2021 S. 1670-1682
Labenz, Christian; Toenges, Gerrit; Galle, Peter et al.
Derivation and validation of the NAFLD cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis and to predict liver-related outcomesJOURNAL OF HEPATOLOGY. Bd. 75. 2021 S. S556-S557
Erhardtsen, Elisabeth; Rasmussen, Daniel G. K.; Frederiksen, Peder et al.
Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosisJHEP REPORTS. Bd. 3. H. 4. 2021
Docherty, Matt; Regnier, Stephane A.; Capkun, Gorana et al.
Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitisJOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION. Bd. 28. H. 6. 2021 S. 1235-1241
Schmitt, Volker H.; Hobohm, Lukas; Sivanathan, Visvakanth et al.
Diabetes mellitus and its impact on mortality rate and outcome in pulmonary embolismJOURNAL OF DIABETES INVESTIGATION. Bd. 13. H. 4. 2021 S. 725-737
Mozes, Ferenc Emil; Lee, Jenny A.; Selvaraj, Emmanuel Anandraj et al.
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysisGUT. Bd. 71. H. 5. 2021 S. 1006-1019
Schattenberg, Jorn M.; Anstee, Quentin M.; Caussy, Cyrielle et al.
Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature reviewEXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY. Bd. 15. H. 11. 2021 S. 1253-1266
Franck, Caspar; Zimmermann, Nadja; Goni, Elisabetta et al.
Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric CancerJOURNAL OF GASTROINTESTINAL AND LIVER DISEASES. Bd. 30. H. 4. 2021 S. 431-437
Schattenberg, Jorn M.; Lazarus, Jeffrey V.; Newsome, Philip N. et al.
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysisLIVER INTERNATIONAL. Bd. 41. H. 6. 2021 S. 1227-1242
Albert, Joerg; Weinmann, Arndt; Rathmayer, Markus et al.
DRG Update Autumn 2021ZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 59. H. 12. 2021 S. 1426-1438
Fontana, Elisa; Meyers, Jeff; Sobrero, Alberto et al.
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and OxaliplatinJOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 36. 2021 S. 4009-+
Fontana, Elisa; Meyers, Jeffrey P.; Sobrero, Alberto F. et al.
Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Armandi, Angelo; Schattenberg, Joern M.
Editorial: the polygenic risk of cirrhosis developmentALIMENTARY PHARMACOLOGY & THERAPEUTICS. Bd. 53. H. 7. 2021 S. 849-850
Kudo, Masatoshi; Galle, Peter R.; Brandi, Giovanni et al.
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2JHEP REPORTS. Bd. 3. H. 2. 2021
Dietz, Julia; Spengler, Ulrich; Mullhaupt, Beat et al.
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 InfectionsCLINICAL GASTROENTEROLOGY AND HEPATOLOGY. Bd. 19. H. 1. 2021 S. 195-+
Michel, Maurice; Hess, Cornelius; Kaps, Leonard et al.
Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosisSCIENTIFIC REPORTS. Bd. 11. H. 1. 2021
Smyth, Elizabeth Catherine; Peeters, Ellen; Knoedler, Maren Kristina et al.
EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/ or R1)-An open-label randomized controlled phase II study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Czauderna, Carolin; Poplawski, Alicia; O'Rourke, Colm J. et al.
Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesisJCI INSIGHT. Bd. 6. H. 17. 2021
Haeuser, Friederike; Sprinzl, Martin F.; Dreis, Kim J. et al.
Evaluation of a laboratory-based high-throughput SARS-CoV-2 antigen assay for non-COVID-19 patient screening at hospital admissionMEDICAL MICROBIOLOGY AND IMMUNOLOGY. Bd. 210. H. 2-3. 2021 S. 165-171
Gerges, Christian; Neumann, ?; Ishaq, Sauid et al.
Evaluation of a novel colonoscope offering flexibility adjuster - a retrospective observational studyTHERAPEUTIC ADVANCES IN GASTROENTEROLOGY. Bd. 14. 2021
Neumann, Helmut; Kreft, Andreas; Sivanathan, Visvakanth et al.
Evaluation of novel LCI CAD EYE system for real time detection of colon polypsPLOS ONE. Bd. 16. H. 8. 2021
Deutschbein, Timo; Jaursch-Hancke, Cornelia; Knappe, Ulrich J. et al.
First German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary TumorsEXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES. Bd. 129. H. 3. 2021 S. 250-264
Moehler, Markus H.; Shitara, Kohei; Garrido, Marcelo et al.
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Moehler, M.; Shitara, K.; Garrido, M. et al.
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy and safety data from CheckMate 649ONCOLOGY RESEARCH AND TREATMENT. Bd. 44. 2021 S. 79-80
Janjigian, Yelena Y.; Shitara, Kohei; Moehler, Markus et al.
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialLANCET. Bd. 398. H. 10294. 2021 S. 27-40
Moehler, M.; Valle, J. W.; Hollebecque, A. et al.
Foenix-CCA2 quality of life data for Futibatinib-treated intrahepatic cholangiocarcinoma (ICCA) patients with FGFR2 fusions/rearrangementsONCOLOGY RESEARCH AND TREATMENT. Bd. 44. 2021 S. 223-224
Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas et al.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trialBRITISH JOURNAL OF CANCER. Bd. 124. H. 3. 2021 S. 587-594
Vollmar, Johanna; Kim, Yong Ook; Marquardt, Jens Uwe et al.
Functional inhibition of Oct leads to HNF4 alpha upregulationEXPERIMENTAL AND THERAPEUTIC MEDICINE. Bd. 21. H. 4. 2021
McNamara, Mairead Geraldine; Bridgewater, John A.; Goyal, Lipika et al.
Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 3. 2021
Sen, Partho; Govaere, Olivier; Sinioja, Tim et al.
Genome-scale metabolic modeling of human hepatocytes reveals dysregulation of glycosphingolipid pathways in progressive non-alcoholic fatty liver diseaseJOURNAL OF HEPATOLOGY. Bd. 75. 2021 S. S256-S256
Anstee, Quentin M.; Darlay, Rebecca; Cockell, Simon et al.
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort (vol 12, pg 505, 2020)JOURNAL OF HEPATOLOGY. Bd. 74. H. 5. 2021 S. 1274-1275
Engelmann, Cornelius; Herber, Adam; Franke, Annegret et al.
Granulocyte-colony stimulating factor (G-CSF) to treat acute-on- chronic liver failure: A multicenter randomized trial (GRAFT study)JOURNAL OF HEPATOLOGY. Bd. 75. H. 6. 2021 S. 1346-1354
Engelmann, Cornelius; Herber, Adam; Ildh, Tony et al.
GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO TREAT ACUTE-ON-CHRONIC LIVER FAILURE; RESULTS OF THE FIRST MULTICENTER RANDOMIZED TRIAL (GRAFT STUDY)GUT. Bd. 70. 2021 S. A6-A6
Krieger, Christine C.; Kahaly, George J.; Azam, Asma et al.
Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical AssaysTHYROID. 2021
Moehler, M.; Elimova, E.; Blum, ? et al.
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649ONCOLOGY RESEARCH AND TREATMENT. Bd. 44. 2021 S. 214-215
Wyrwicz, Lucjan; Elimova, Elena; Blum, Steven I. et al.
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Elimova, Elena; Wyrwicz, Lucjan; Blum, Steven I. et al.
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Results of nivolumab plus chemotherapy (NIVO plus chemo) versus chemo from CheckMate 649JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 28. 2021
Michel, Maurice; Spinelli, Francesca; Grambihler, Annette et al.
Health-related quality of life in patients with autoimmune hepatitisQUALITY OF LIFE RESEARCH. Bd. 30. H. 10. 2021 S. 2853-2861
Graf, Christiana; Arncken, Jeannette; Lange, Christian M. et al.
Hepatic sarcoidosis: Clinical characteristics and outcomeJHEP REPORTS. Bd. 3. H. 6. 2021
Maehringer-Kunz, Aline; Meyer, Franziska I.; Hahn, Felix et al.
Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significanceUNITED EUROPEAN GASTROENTEROLOGY JOURNAL. Bd. 9. H. 5. 2021 S. 590-597
Czauderna, Carolin; Schmidtmann, Irene; Koch, Sandra et al.
High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinomaUNITED EUROPEAN GASTROENTEROLOGY JOURNAL. Bd. 9. H. 3. 2021 S. 388-397
Koessler, Thibaud; Alsina, Maria; Arnold, Dirk et al.
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer groupBRITISH JOURNAL OF CANCER. Bd. 125. H. 7. 2021 S. 911-919
Stoehr, Fabian; Mueller, Lukas; Brady, Adrian et al.
How COVID-19 kick-started online learning in medical education-The DigiMed studyPLOS ONE. Bd. 16. H. 9. 2021
Ducreux, Michel; Zhu, Andrew X.; Cheng, Ann-Lii et al.
IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Zhu, Andrew X.; Finn, Richard; Ducreux, Michel et al.
IMbrave150: EXPLORATORY EFFICACY AND SAFETY OF ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WITH NON-VIRAL ETIOLOGY IN A GLOBAL PHASE III STUDYHEPATOLOGY. Bd. 74. 2021 S. 646A-647A
Breder, Valeriy Vladimirovich; Vogel, Arndt; Merle, Philippe et al.
IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Finn, Richard S.; Qin, Shukui; Ikeda, Masafumi et al.
IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)SWISS MEDICAL WEEKLY. Bd. 151. 2021 S. 25-26
Finn, Richard S.; Qin, Shukui; Ikeda, Masafumi et al.
IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).CANCER RESEARCH. Bd. 81. H. 13. 2021
Finn, Richard S.; Qin Shukui, ?; Ikeda, Masafumi et al.
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 3. 2021
Galle, P.; Finn, R. S.; Qin, S. et al.
IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)ONCOLOGY RESEARCH AND TREATMENT. Bd. 44. 2021 S. 34-34
Boedecker, Simone C.; Luessi, Felix; Engel, Sinah et al.
Immunoadsorption and plasma exchange-Efficient treatment options for neurological autoimmune diseasesJOURNAL OF CLINICAL APHERESIS. Bd. 37. H. 1. 2021 S. 70-81
Mueller, Lukas; Hahn, Felix; Maehringer-Kunz, Aline et al.
Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY IndexCANCERS. Bd. 13. H. 19. 2021
Mueller, Lukas; Hahn, Felix; Maehringer-Kunz, Aline et al.
Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?FRONTIERS IN ONCOLOGY. Bd. 11. 2021
Schmitt, Volker H.; Hobohm, Lukas; Wenzel, Philip et al.
Impact of diabetes mellitus on mortality rate and outcome in pulmonary embolismINTERNIST. Bd. 62. H. SUPPL 2. 2021 S. 174-174
Labenz, Christian; Kostev, Karel; Armandi, Angelo et al.
Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in GermanyUNITED EUROPEAN GASTROENTEROLOGY JOURNAL. Bd. 9. H. 7. 2021 S. 829-836
Ugradar, Shoaib; Wang, Yao; Mester, Tunde et al.
Improvement of asymmetric thyroid eye disease with teprotumumabBRITISH JOURNAL OF OPHTHALMOLOGY. Bd. 106. H. 6. 2021 S. 755-759
Mohr, A.; Bodenstein, M.; Sagoschen, I et al.
Incompatibility-reducing infusion charts for pharmacotherapy of intensive care patientsANASTHESIOLOGIE & INTENSIVMEDIZIN. Bd. 62. 2021 S. 528-537
Mozes, Ferenc E.; Lee, Jenny; Selvaraj, Emmanuel et al.
INDIVIDUAL PATIENT DATA META-ANALYSIS OF THE DIAGNOSTIC PERFORMANCE OF NON-INVASIVE TESTS IN SCREENING "AT RISK" NASHHEPATOLOGY. Bd. 74. 2021 S. 51A-53A
Mozes, Ferenc; Lee, Jenny; Selvaraj, Emmanuel et al.
Individual patient data meta-analysis of the diagnostic performance of single and sequentially combined non-invasive tests in detecting advanced fibrosisJOURNAL OF HEPATOLOGY. Bd. 75. 2021 S. S259-S260
Ernst, Mareike; Braehler, Elmar; Otten, Danielle et al.
Inflammation predicts new onset of depression in men, but not in women within a prospective, representative community cohortSCIENTIFIC REPORTS. Bd. 11. H. 1. 2021
Tanislav, Christian; Trommer, Kathleen; Labenz, Christian et al.
Inflammatory Bowel Disease as a Precondition for Stroke or TIA: A Matter of Crohn's Disease Rather than Ulcerative ColitisJOURNAL OF STROKE & CEREBROVASCULAR DISEASES. Bd. 30. H. 7. 2021
Bartsch, Fabian; Heuft, Lisa-Katharina; Baumgart, Janine et al.
Influence of Lymphangio (L), Vascular (V), and Perineural (Pn) Invasion on Recurrence and Survival of Resected Intrahepatic CholangiocarcinomaJOURNAL OF CLINICAL MEDICINE. Bd. 10. H. 11. 2021
Mohr, A; Bodenstein, M; Sagoschen, I et al.
Inkompatibilitätenreduzierende Infusionschemata für die Arzneimitteltherapie bei IntensivpatientenAnästhesiologie & Intensivmedizin. Bd. 62. 2021 S. 522-537
Pavlakis, N.; Shitara, K.; Sjoquist, K. et al.
INTEGRATE IIb: A randomised phase III open label study of regorafenib plus nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)ANNALS OF ONCOLOGY. Bd. 32. 2021 S. S1074-S1074
Schuster, Alexander Karl-Georg; Aghayeva, Fidan; Wagner, Felix Mathias et al.
Intraocular pressure and its relation to ocular geometry: results from the Gutenberg Health StudyINVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. Bd. 62. H. 8. 2021
Ridder, Dirk Andreas; Schindeldecker, Mario; Weinmann, Arndt et al.
Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular CarcinomaCANCERS. Bd. 13. H. 4. 2021
Malin, Jakob J.; Spinner, Christoph D.; Janssens, Uwe et al.
Key summary of German national treatment guidance for hospitalized COVID-19 patients (Jul, 10.1007/s15010-021-01645-2, 2021)INFECTION. Bd. 50. H. 1. 2021 S. 107-108
Malin, Jakob J.; Spinner, Christoph D.; Janssens, Uwe et al.
Key summary of German national treatment guidance for hospitalized COVID-19 patients Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)INFECTION. Bd. 50. H. 1. 2021 S. 93-106
Shah, Manish A.; Bennouna, Jaafar; Doi, Toshihiko et al.
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinomaFUTURE ONCOLOGY. Bd. 17. H. 10. 2021 S. 1143-1153
Schmidtke, Lisa; Meineck, Myriam; Saurin, Sabrina et al.
Knockout of the KH-Type Splicing Regulatory Protein Drives Glomerulonephritis in MRL-Fas(lpr) MiceCELLS. Bd. 10. H. 11. 2021
Emrich, Tilman; Schattenberg, Jorn M.
Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-the role for non-invasive testingALIMENTARY PHARMACOLOGY & THERAPEUTICS. Bd. 54. H. 2. 2021 S. 214-215
Labenz, Christian; Schattenberg, Jorn M.
Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' replyALIMENTARY PHARMACOLOGY & THERAPEUTICS. Bd. 53. H. 5. 2021 S. 673-673
Mueller-Calleja, Nadine; Hollerbach, Anne; Royce, Jennifer et al.
Lipid presentation by the protein C receptor links coagulation with autoimmunitySCIENCE. Bd. 371. H. 6534. 2021 S. 1121-+
Labenz, Christian; Toenges, Gerrit; Woerns, Marcus-Alexander et al.
Liver injury in patients with severe acute respiratory syndrome coronavirus-2 infection: a systematic review and meta-analysisEUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. Bd. 33. H. 9. 2021 S. 1194-1200
Lang, Hauke; Baumgart, Janine; Heinrich, Stefan et al.
Liver Resection for Intrahepatic Cholangiocarcinoma-Single-Center Experience with 286 Patients Undergoing Surgical Exploration over a Thirteen Year PeriodJOURNAL OF CLINICAL MEDICINE. Bd. 10. H. 16. 2021
Dietz, Julia; Graf, Christiana; Muellhaupt, Beat et al.
LONG-TERM PERSISTENCE OF RESISTANCE-ASSOCIATED SUBSTITUTIONS (RASS) AFTER DAA TREATMENT FAILURE IN PATIENTS WITH CHRONIC HCV INFECTIONHEPATOLOGY. Bd. 74. 2021 S. 594A-595A
Catenacci, Daniel V. T.; Rosales, Minori; Chung, Hyun Cheol et al.
MAHOGANY: margetuximab combination in HER2(+) unresectable/metastatic gastric/gastroesophageal junction adenocarcinomaFUTURE ONCOLOGY. Bd. 17. H. 10. 2021 S. 1155-1164
Catenacci, Daniel V. T.; Rosales, Minori Koshiji; Chung, Hyun Cheol et al.
Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) plus /- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+gastroesophageal junction (GEJ) or gastric cancer (GC).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 3. 2021
Catenacci, D.; Rosales, M. Koshiji; Chung, H. et al.
Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) plus /- chemotherapy in first-line therapy of advanced/metastatic HER2+gastroesophageal junction or gastric cancerANNALS OF ONCOLOGY. Bd. 32. 2021 S. S146-S146
Gehrke, Nadine; Straub, Beate K.; Ruehle, Frank et al.
METABOLIC HEPATOCARCINOGENESIS IS SLOWED IN HEPATOCYTES LACKING IL-1R1HEPATOLOGY. Bd. 74. 2021 S. 1079A-1079A
Heinrich, Stefan; Mittler, Jens; Theurer, Juliane et al.
Microvascular invasion of hepatocellular carcinoma predicts microvascular invasion of its recurrence: potential implications for salvage liver transplantation?HEPATOBILIARY SURGERY AND NUTRITION. 2021
Haber, Philipp K.; Castet, Florian; Torres-Martin, Miguel et al.
MOLECULAR MARKERS OF RESPONSE TO ANTI-PD1 THERAPY IN ADVANCED HEPATOCELLULAR CARCINOMAHEPATOLOGY. Bd. 74. 2021 S. 109A-110A
Haber, Philipp K.; Torres-Martin, Miguel; Dufour, Jean-Francois et al.
Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Schuele, Martin; Butto, Tamer; Dewi, Sri et al.
mTOR Driven Gene Transcription Is Required for Cholesterol Production in Neurons of the Developing Cerebral CortexINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Bd. 22. H. 11. 2021
Rinke, Anja; Maintz, Christoph; Mueller, Lothar et al.
Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and AustriaEXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES. Bd. 129. H. 7. 2021 S. 500-509
Gairing, Simon J.; Kloeckner, Roman; Pitton, Michael B. et al.
Multidisciplinary approach to the complex treatment for noncirrhotic portal hypertension - case-report-based discussionZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 59. H. 01. 2021 S. 43-49
Stahler, Arndt; Heinemann, Volker; Holch, Julian Walter et al.
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3)INTERNATIONAL JOURNAL OF CANCER. Bd. 149. H. 11. 2021 S. 1935-1943
Moehler, Markus
My Highlights at ASCO 2021: Breakthrough in Immunotherapy for Esophageal and Gastric CancerZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 59. H. 11. 2021 S. 1240-1241
Armandi, Angelo; Schattenberg, Joern M.
NAFLD between genes and environment: what drives fibrogenesis?GUT. Bd. 70. H. 5. 2021 S. 815-+
Alqahtani, Saleh A.; Schattenberg, Joern M.
NAFLD in the ElderlyCLINICAL INTERVENTIONS IN AGING. Bd. 16. 2021 S. 1633-1649
Pfister, Dominik; Nunez, Nicolas Gonzalo; Pinyol, Roser et al.
NASH limits anti-tumour surveillance in immunotherapy-treated HCCNATURE. Bd. 592. H. 7854. 2021 S. 450-+
Sun, Qian; Mehl, Sebastian; Renko, Kostja et al.
Natural Autoimmunity to Selenoprotein P Impairs Selenium Transport in Hashimoto's ThyroiditisINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Bd. 22. H. 23. 2021
Janjigian, Y. Y.; Ajani, J. A.; Moehler, M. et al.
Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 studyANNALS OF ONCOLOGY. Bd. 32. 2021 S. S1329-S1330
Falter, Tanja; Rossmann, Heidi; Menge, Philipp et al.
No Evidence for Classic Thrombotic Microangiopathy in COVID-19JOURNAL OF CLINICAL MEDICINE. Bd. 10. H. 4. 2021
Hahad, Omar; Beutel, Manfred; Michal, Matthias et al.
Noise annoyance in the German general population Prevalence and determinants in the Gutenberg Health StudyHERZ. Bd. 47. H. 3. 2021 S. 265-279
Schattenberg, Joern; Gomez, Manuel Romero; Shaikh, Anum et al.
Non-alcoholic steatohepatitis-related costs changes in the context of fibrosis progression status in European patientsJOURNAL OF HEPATOLOGY. Bd. 75. 2021 S. S398-S399
Wild, Johannes; Distelmeier, Simon; Keil, Philip et al.
Non-bacterial thrombotic endocarditis in a patient with pancreatic carcinomaECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES. Bd. 38. H. 8. 2021 S. 1455-1458
Michel, Maurice; Huber, Yvonne; Schattenberg, Joern M.
Non-invasive Diagnosis of Liver Fibrosis in Patients with non-alcoholic Fatty Liver Disease (NAFLD)GASTROENTEROLOGE. Bd. 16. H. 4. 2021 S. 278-279
Alqahtani, Saleh A.; Schattenberg, Jorn M.
Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practiceEXPERT REVIEW OF MOLECULAR DIAGNOSTICS. Bd. 21. H. 10. 2021 S. 1065-1078